Showing results (111-120 of 223) with videos related to
Sort By:
Pageof 23
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 17, 2019
Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?Anouchka Modesto, Thibaut Galissier, Amélie Lusque, et al.Current Clinical Pharmacology|November 16, 2011
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancerPeggy Gandia, Cecile Arellano, Quentin Chalret du Rieu, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyHenri Roché, Louise Yelle, Francesco Cognetti, et al.Investigational New Drugs|February 12, 2009
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxicsNicolas Penel, Jean-Pierre Delord, Marie-Edith Bonneterre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.The Oncologist|April 27, 2005
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forumRomán Pérez-Soler, Jean Pierre Delord, Allan Halpern, et al.Cancer Letters|September 26, 2015
F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancerBenoît Thibault, Emily Clement, Grégoire Zorza, et al.Oncotarget|January 10, 2018
Fluorescence-guided surgery for cancer patients: a proof of concept study on human xenografts in mice and spontaneous tumors in petsEliane Mery, Muriel Golzio, Stephanie Guillermet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trialsCharles Ferté, Marianna Fernandez, Antoine Hollebecque, et al.Pageof 23